Vivek Ramaswamy’s Dermavant team looks to take on Amgen’s $13.4B psoriasis contender Otezla with a promising PhIII readout for a topical rival

John Carroll

Editor & Founder

At first glance, you might not be too impressed with the data from Dermavant’s Phase IIIs for their psoriasis contender tapinarof. The results pale in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vivek Ramaswamy’s Dermavant team looks to take on Amgen’s $13.4B psoriasis contender Otezla with a promising PhIII readout for a topical rival

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Biotech VC firm outlines plans for $100M fund

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Regulatory RNA startup CAMP4 files for IPO as more biotechs line up listings

Here's what today's Fed rate cut means for biotech, pharma and venture capital

Breaking down silos with a new quantitative approach to drug development

Vivek Ra­maswamy’s Der­ma­vant team looks to take on Am­gen’s $13.4B pso­ri­a­sis con­tender Ote­zla with a promis­ing PhI­II read­out for a top­i­cal ri­val

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Vivek Ramaswamy’s Dermavant team looks to take on Amgen’s $13.4B psoriasis contender Otezla with a promising PhIII readout for a topical rival